Evidence map›Paper›PMID 38304158›Full record

ArticlePorto biomedical journal

Treatment of idiopathic overactive bladder with botulinum toxin: real-life results and patients' expectations.

Pedro Abreu-Mendes, Inês Portugal-Rodrigues, Luis Vale, Paulo Dinis, Francisco Cruz, Tiago Antunes-Lopes, Carlos Martins-Silva

Open access · diamondAbstract read
In one paragraph

Article in Porto biomedical journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Pedro Abreu-MendesServiço de Urologia, Centro Hospitalar Universitário de São João.
Inês Portugal-RodriguesFaculdade de Medicina, Universidade do Porto, Porto, Portugal.
Luis ValeServiço de Urologia, Centro Hospitalar Universitário de São João.
Paulo DinisServiço de Urologia, Centro Hospitalar Universitário de São João.
Francisco CruzServiço de Urologia, Centro Hospitalar Universitário de São João.
Tiago Antunes-LopesServiço de Urologia, Centro Hospitalar Universitário de São João.
Carlos Martins-SilvaServiço de Urologia, Centro Hospitalar Universitário de São João.
Universidade do Porto · PTHospital de São João · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Overactive bladder (OAB) is a prevalent syndrome affecting 11% to 16% of the adult population. When first-line pharmacological therapy is not effective, intradetrusorial injections of onabotulinumtoxinA (BTX-A) might have an important role in controlling symptoms. The main aim of this study was to access both the efficacy and safety of intradetrusor injections of 100U BTX-A in real clinical practice, among women with idiopathic OAB (iOAB). Methods: Retrospective study, based on clinical diaries in 136 iOAB female patients, with or without urinary incontinence, submitted to BTX-A injections, between 2005 and 2018 in a tertiary university hospital. Positive response was considered only when the patient mentioned she had great improvement after the injection, otherwise, it was considered negative. Results: A positive response was obtained in 90 patients (66%) after the first injection. Women with a positive response after the first treatment had 7.5 times more chances to improve with the second ( Conclusion: In real clinical practice, BTX-A injection is an effective (66%) and safe treatment, capable of improving quality of life. Moreover, responding to the first injection seems to predict good clinical outcomes in the second treatment. This procedure can be done with minimal restrictions.

Indexed as

intravesical treatmentonabotulinumtoxinAoveractive bladderurgency urinary incontinenceurinary

Identifiers

PMID38304158
PMCPMC10830074
OpenAlexW4280633329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.